Abstract
Background: Immune checkpoint inhibitors confer significant clinical benefit by bolstering immune-system activity, however, they also produce a spectrum of immune-related adverse events (irAEs). Rapid recognition and timely treatment of these patients is essential for improved outcomes. Methods: We conducted a systematic review of English-language articles in MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane CENTRAL databases on patients with head and neck cancer treated with immune checkpoint inhibitors who developed treatment-related adverse events. Results: Of 1715 unique citations, 11 studies met inclusion criteria. Eight patients with serious irAEs were reported from case reports and case series. Overall, 46 treatment-related AEs were identified from the pooled 791 patients with at least 12 having potential relevance to irAEs. The most frequent AEs observed in patients receiving PD-1 inhibitors involved the endocrine, cutaneous, and gastrointestinal systems. Conclusions: Characterizing irAEs in longitudinal studies is needed for developing strategies for their prompt recognition and management.
Original language | English (US) |
---|---|
Pages (from-to) | 4036-4050 |
Number of pages | 15 |
Journal | Head and Neck |
Volume | 41 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2019 |
ASJC Scopus subject areas
- Otorhinolaryngology